The GW Pharmaceuticals PLC- (GWPH) Lowered to “Sell” at Zacks Investment Research

The GW Pharmaceuticals PLC- (GWPH) Lowered to “Sell” at Zacks Investment Research

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, May 15th.

A number of other equities research analysts also recently issued reports on the stock. TheStreet downgraded shares of GW Pharmaceuticals PLC- from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 9th. Maxim Group assumed coverage on shares of GW Pharmaceuticals PLC- in a research note on Thursday, April 20th. They set a “buy” rating and a $135.00 price target on the stock. Goldman Sachs Group Inc reaffirmed a “buy” rating and set a $185.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, February 22nd. Finally, Cowen and Company set a $135.00 price target on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research note on Monday, February 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $144.50.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at 101.76 on Monday. The company’s 50 day moving average is $109.73 and its 200 day moving average is $117.72. The company’s market cap is $2.58 billion. GW Pharmaceuticals PLC- has a 12-month low of $79.62 and a 12-month high of $137.88. GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.50) by $0.20. The business had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.07 million. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. GW Pharmaceuticals PLC-‘s revenue for the quarter was down 23.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) EPS. Analysts forecast that GW Pharmaceuticals PLC- will post ($5.34) earnings per share for the current fiscal year.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at 101.76 on Monday. The company’s 50 day moving average is $109.73 and its 200 day moving average is $117.72. The company’s market cap is $2.58 billion. GW Pharmaceuticals PLC- has a 12-month low of $79.62 and a 12-month high of $137.88. Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rothschild Capital Partners LLC boosted its position in GW Pharmaceuticals PLC- by 685.3% in the third quarter. Rothschild Capital Partners LLC now owns 23,560 shares of the biopharmaceutical company’s stock worth $3,127,000 after buying an additional 20,560 shares during the period. Scopia Capital Management LP bought a new position in GW Pharmaceuticals PLC- during the third quarter worth approximately $250,218,000. Tocqueville Asset Management L.P. boosted its position in GW Pharmaceuticals PLC- by 1.8% in the third quarter. Tocqueville Asset Management L.P. now owns 28,400 shares of the biopharmaceutical company’s stock worth $3,770,000 after buying an additional 500 shares during the last quarter. Jana Partners LLC bought a new position in GW Pharmaceuticals PLC- during the third quarter worth approximately $5,522,000. Finally, Pictet Asset Management Ltd. boosted its position in GW Pharmaceuticals PLC- by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares during the last quarter. Institutional investors and hedge funds own 72.30% of the company’s stock.

About GW Pharmaceuticals PLC- GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GWPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment